Urdhva Raval
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Urdhva Raval has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Giulio Maria Pasinetti
Department of Neurology, Icahn School of Medicine at Mount Sinai
5 shared publications Emma Zeng
Icahn School of Medicine at Mount Sinai New York NY USA
2 shared publicationsJoyce M. Harary
Department of Neurology, Mount Sinai School of Medicine , New York, NY 10029, USA
2 shared publications- Sean X. Naughton
Icahn School of Medicine at Mount Sinai, Center for Molecular Integrative Neuroresilience New York NY USA
2 shared publications Al Rahim
Icahn School of Medicine at Mount Sinai, Center for Molecular Integrative Neuroresilience New York NY USA
1 shared publicationElizabeth Griggs
Icahn School of Medicine at Mount Sinai, Center for Molecular Integrative Neuroresilience New York NY USA
1 shared publication
Latest Publications
- 1 February 2022
- Vol. 17 (Suppl 3)
COVID‐19 and Alzheimer’s disease: Meninges‐mediated neuropathology
SARS‐CoV‐2 the causative agent of COVID‐19 displays a broad range of pathophysiology. Cytokine storms associated with COVID‐19 damage the blood‐brain barrier (BBB) and allow pro‐inflammatory factors to invade the brain, further promoting neurodegeneration. While SARS‐CoV‐2 viral RNA and proteins have been detected in brain tissues, the mechanisms of neuroinvasion remain unknown. COVID‐19 has had a disproportionate impact on those suffering from neurodegenerative disorders such as Alzheimer’s disease (AD). Understanding the mechanisms of SARS‐CoV‐2 neuroinvasion is crucial to study the long‐term neurocognitive effects of COVID‐19 on AD pathology. Viruses can infiltrate the brain through the meninges via infected immune cells. The meninges regulate the immune surveillance of the brain and play a key role in the efflux of pathogens from the brain. Meningeal dysfunction has been demonstrated to exacerbate amyloid‐beta pathogenesis. In this study, we explore the neuroinvasion pathway of SARS‐CoV‐2 through the meninges and its effect on AD pathology. 5x FAD x hACE2 mice were inoculated intranasally with a sublethal dose of SARS‐CoV‐2. The mice were maintained for 2 weeks. Mouse brains and meninges were harvested. The tissue was stained and immunofluorescence imaging was conducted to study viral proliferation and immune responses. Histo‐cytometry was conducted for quantitative imaging analysis. Gene expression studies were done using Nanostring assays. All experiments involving the SARS‐Cov‐2 virus were carried out in a BSL3 facility. This ongoing study demonstrates the proliferation of the SARS‐CoV‐2 virus in the brain via meningeal lymphatics. SARS‐CoV‐2 infection resulted in increased neuroinflammation. Additionally, inflammatory responses induced meningeal dysfunction resulting in increased amyloid‐beta pathology and cerebrospinal fluid drainage. Given the increasing evidence for a viral hypothesis of Alzheimer’s Disease it is extremely important to study the neurodegenerative effects of COVID‐19 which has affected millions worldwide. We demonstrate that SARS‐CoV‐2 infiltrates the brain via the meninges promoting neuroinflammation. Furthermore, amyloid‐beta pathologies are exacerbated by COVID‐19 in animal models providing preclinical evidence of the long‐term neurodegenerative effects of COVID‐19.
- 1 February 2022
- Vol. 17 (Suppl 3)
COVID‐19 and Alzheimer’s disease: Meninges‐mediated neuropathology
SARS‐CoV‐2 the causative agent of COVID‐19 displays a broad range of pathophysiology. Cytokine storms associated with COVID‐19 damage the blood‐brain barrier (BBB) and allow pro‐inflammatory factors to invade the brain, further promoting neurodegeneration. While SARS‐CoV‐2 viral RNA and proteins have been detected in brain tissues, the mechanisms of neuroinvasion remain unknown. COVID‐19 has had a disproportionate impact on those suffering from neurodegenerative disorders such as Alzheimer’s disease (AD). Understanding the mechanisms of SARS‐CoV‐2 neuroinvasion is crucial to study the long‐term neurocognitive effects of COVID‐19 on AD pathology. Viruses can infiltrate the brain through the meninges via infected immune cells. The meninges regulate the immune surveillance of the brain and play a key role in the efflux of pathogens from the brain. Meningeal dysfunction has been demonstrated to exacerbate amyloid‐beta pathogenesis. In this study, we explore the neuroinvasion pathway of SARS‐CoV‐2 through the meninges and its effect on AD pathology. 5x FAD x hACE2 mice were inoculated intranasally with a sublethal dose of SARS‐CoV‐2. The mice were maintained for 2 weeks. Mouse brains and meninges were harvested. The tissue was stained and immunofluorescence imaging was conducted to study viral proliferation and immune responses. Histo‐cytometry was conducted for quantitative imaging analysis. Gene expression studies were done using Nanostring assays. All experiments involving the SARS‐Cov‐2 virus were carried out in a BSL3 facility. This ongoing study demonstrates the proliferation of the SARS‐CoV‐2 virus in the brain via meningeal lymphatics. SARS‐CoV‐2 infection resulted in increased neuroinflammation. Additionally, inflammatory responses induced meningeal dysfunction resulting in increased amyloid‐beta pathology and cerebrospinal fluid drainage. Given the increasing evidence for a viral hypothesis of Alzheimer’s Disease it is extremely important to study the neurodegenerative effects of COVID‐19 which has affected millions worldwide. We demonstrate that SARS‐CoV‐2 infiltrates the brain via the meninges promoting neuroinflammation. Furthermore, amyloid‐beta pathologies are exacerbated by COVID‐19 in animal models providing preclinical evidence of the long‐term neurodegenerative effects of COVID‐19.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Development of a functional 3D brain organoid with microvasculature and a blood‐brain barrier
Background: Brain organoids are self‐assembled 3D cell aggregates developed from pluripotent stem cells with various cell types and extracellular structures that resemble the embryonic human brain. Induced pluripotent stem cells (iPSC) based organoids show great promise in disease modeling applications. Our previous work has validated the use of novel polyphenolic compounds to combat neurodegenerative diseases in animal and traditional cell culture models. The goal of the present study is to continue to explore the development of a functional brain organoid system with microvasculature and a blood‐brain barrier using iPSCs.Method: iPSCs were differentiated into neurons, astrocytes, pericytes, oligodendrocytes, brain microvascular endothelial cells, and other relevant cell types. The organoid was developed using previously published protocols. The blood‐brain barrier was constructed by co‐culturing the different cell types.Result: In this ongoing study, we demonstrate the development of a more accurate and functional brain organoid system with microvasculature and a blood‐brain barrier using iPSCs.Conclusion: Our organoid will serve as a model for neurodegenerative diseases, drug discovery and the screening of novel polyphenolic compounds from dietary flavanols which have been recently associated with reduced risk of developing Alzheimer’s Dementia.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Development of a functional 3D brain organoid with microvasculature and a blood‐brain barrier
Background: Brain organoids are self‐assembled 3D cell aggregates developed from pluripotent stem cells with various cell types and extracellular structures that resemble the embryonic human brain. Induced pluripotent stem cells (iPSC) based organoids show great promise in disease modeling applications. Our previous work has validated the use of novel polyphenolic compounds to combat neurodegenerative diseases in animal and traditional cell culture models. The goal of the present study is to continue to explore the development of a functional brain organoid system with microvasculature and a blood‐brain barrier using iPSCs.Method: iPSCs were differentiated into neurons, astrocytes, pericytes, oligodendrocytes, brain microvascular endothelial cells, and other relevant cell types. The organoid was developed using previously published protocols. The blood‐brain barrier was constructed by co‐culturing the different cell types.Result: In this ongoing study, we demonstrate the development of a more accurate and functional brain organoid system with microvasculature and a blood‐brain barrier using iPSCs.Conclusion: Our organoid will serve as a model for neurodegenerative diseases, drug discovery and the screening of novel polyphenolic compounds from dietary flavanols which have been recently associated with reduced risk of developing Alzheimer’s Dementia.
- Open Access
- 29 July 2020
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (3) , 74
The Viral Hypothesis in Alzheimer’s Disease: Novel Insights and Pathogen-Based Biomarkers
Early diagnosis of Alzheimer’s disease (AD) and the identification of significant risk factors are necessary to better understand disease progression, and to develop intervention-based therapies prior to significant neurodegeneration. There is thus a critical need to establish biomarkers which can predict the risk of developing AD before the onset of cognitive decline. A number of studies have indicated that exposure to various microbial pathogens can accelerate AD pathology. Additionally, several studies have indicated that amyloid-β possess antimicrobial properties and may act in response to infection as a part of the innate immune system. These findings have led some to speculate that certain types of infections may play a significant role in AD pathogenesis. In this review, we will provide an overview of studies which suggest pathogen involvement in AD. Additionally, we will discuss a number of pathogen-associated biomarkers which may be effective in establishing AD risk. Infections that increase the risk of AD represent a modifiable risk factor which can be treated with therapeutic intervention. Pathogen-based biomarkers may thus be a valuable tool for evaluating and decreasing AD risk across the population.
- 29 July 2020
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (3) , 74
Open AccessThe Viral Hypothesis in Alzheimer’s Disease: Novel Insights and Pathogen-Based Biomarkers
Early diagnosis of Alzheimer’s disease (AD) and the identification of significant risk factors are necessary to better understand disease progression, and to develop intervention-based therapies prior to significant neurodegeneration. There is thus a critical need to establish biomarkers which can predict the risk of developing AD before the onset of cognitive decline. A number of studies have indicated that exposure to various microbial pathogens can accelerate AD pathology. Additionally, several studies have indicated that amyloid-β possess antimicrobial properties and may act in response to infection as a part of the innate immune system. These findings have led some to speculate that certain types of infections may play a significant role in AD pathogenesis. In this review, we will provide an overview of studies which suggest pathogen involvement in AD. Additionally, we will discuss a number of pathogen-associated biomarkers which may be effective in establishing AD risk. Infections that increase the risk of AD represent a modifiable risk factor which can be treated with therapeutic intervention. Pathogen-based biomarkers may thus be a valuable tool for evaluating and decreasing AD risk across the population.
- Open Access
- 21 July 2020
- Published by Elsevier in Molecular Immunology
- Vol. 125, 172-177
Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes
- 21 July 2020
- Published by Elsevier in Molecular Immunology
- Vol. 125, 172-177
Open AccessCharacterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes
- 30 June 2020
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 76 (1) , 21-25
Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies
There are a number of potential implications for the field of Alzheimer’s disease (AD) stemming from the global spread of SARS-CoV-2. Neuroinflammation is known to be a prominent feature of neurodegeneration and plays a major role in AD pathology. Im
- 30 June 2020
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 76 (1) , 21-25
Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies
There are a number of potential implications for the field of Alzheimer’s disease (AD) stemming from the global spread of SARS-CoV-2. Neuroinflammation is known to be a prominent feature of neurodegeneration and plays a major role in AD pathology. Im
- 27 June 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 20 (7) , 673-686
The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders
Age related neurodegenerative disorders affect millions of people around the world. The role of the gut microbiome (GM) in neurodegenerative disorders has been elucidated over the past few years. D...
- 27 June 2020
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 20 (7) , 673-686
The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders
Age related neurodegenerative disorders affect millions of people around the world. The role of the gut microbiome (GM) in neurodegenerative disorders has been elucidated over the past few years. D...
- Open Access
- 12 May 2020
- Published by Springer Nature in Journal of Exposure Science & Environmental Epidemiology
- Vol. 30 (5) , 776-777
The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection
- 12 May 2020
- Published by Springer Nature in Journal of Exposure Science & Environmental Epidemiology
- Vol. 30 (5) , 776-777
Open AccessThe role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection